7UX Stock Overview A clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Spago Nanomedical AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Spago Nanomedical Historical stock prices Current Share Price SEK 0.015 52 Week High SEK 0.033 52 Week Low SEK 0.012 Beta 2.02 1 Month Change -5.19% 3 Month Change -17.98% 1 Year Change -36.52% 3 Year Change -96.92% 5 Year Change n/a Change since IPO -98.01%
Recent News & Updates
Spago Nanomedical AB (Publ) Announces All Patients in the Second Patient Group Have Been Dosed According to Plan in the Company's Phase I/IIa Study Tumorad-01 with the Candidate Drug 177Lu-SN201 Dec 18
Third quarter 2024 earnings released Nov 07
Spago Nanomedical AB (Publ) Appoints Nomination Committee for Annual General Meeting 2025 Oct 22
Spago Nanomedical AB (publ)'s Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group Aug 27
Second quarter 2024 earnings released Aug 22
New major risk - Market cap size Aug 14 See more updates
Spago Nanomedical AB (Publ) Announces All Patients in the Second Patient Group Have Been Dosed According to Plan in the Company's Phase I/IIa Study Tumorad-01 with the Candidate Drug 177Lu-SN201 Dec 18
Third quarter 2024 earnings released Nov 07
Spago Nanomedical AB (Publ) Appoints Nomination Committee for Annual General Meeting 2025 Oct 22
Spago Nanomedical AB (publ)'s Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group Aug 27
Second quarter 2024 earnings released Aug 22
New major risk - Market cap size Aug 14
New major risk - Financial position Jul 01
New major risk - Share price stability Jun 07
New minor risk - Financial position Jun 01 Spago Nanomedical AB (publ) to Report Q2, 2024 Results on Aug 21, 2024
Spago Nanomedical AB (publ), Annual General Meeting, Jun 10, 2024 May 08
Spago Nanomedical AB (publ) Reports Favorable Data in Breast Cancer Model with Tumorad Apr 24
Spago Nanomedical AB (publ) Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024 Apr 17
Full year 2023 earnings released: kr0.43 loss per share (vs kr0.61 loss in FY 2022) Feb 09
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01 Jan 10
New major risk - Shareholder dilution Dec 22
Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis Dec 20
Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis Dec 15
Spago Nanomedical AB (publ) Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program Dec 07
Third quarter 2023 earnings released Nov 04
Spago Nanomedical AB (publ) Announces Publication of Four New Patent Applications Filed with the European Patent Office Oct 26
Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa Oct 24
High number of new and inexperienced directors Oct 19
Spago Nanomedical AB (publ) Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia Oct 19
High number of new and inexperienced directors Sep 20
New minor risk - Profitability Aug 15
No longer forecast to breakeven Aug 15
Second quarter 2023 earnings released Aug 01
Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02 Jun 28
Spago Nanomedical AB (Publ) Announces Establishment of A Scientific Advisory Board Jun 13
High number of new and inexperienced directors Jun 02
Spago Nanomedical AB (publ) Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study May 23
First quarter 2023 earnings released: kr0.16 loss per share (vs kr0.24 loss in 1Q 2022) May 15
Spago Nanomedical AB (Publ) Elects New Directors May 11
Full year 2022 earnings released: kr0.61 loss per share (vs kr0.99 loss in FY 2021) Feb 05
Spago Nanomedical AB (Publ) Publishes Scientific Paper on Positive Preclinical Data with Tumorad(R) as Treatment of Solid Tumors Jan 11
First Patient Dosed in Spago Nanomedical’S Endometriosis Phase Iia Clinical Study Dec 10
Spago Nanomedical Initiates Clinical Trial with Spagopix in Endometriosis and Concludes SpagoPix -01 Dec 07
Forecast to breakeven in 2023 Nov 25
Spago Nanomedical Gets SpagoPix Abstract Accepted At Breast Cancer Conference Sep 21
Spago Nanomedical Announces Process of Entering Clinical Phase with Its Drug Candidate [177]Lu-SN201 Sep 13
First quarter 2022 earnings released Apr 28
Forecast breakeven date pushed back to 2023 Apr 27 Spago Nanomedical AB (publ), Annual General Meeting, May 18, 2022
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 04
Spago Nanomedical AB (publ) Announces New Results Jan 26
Spago Nanomedical Announces Positive Interim Results from Phase I Study with SpagoPix Jan 18
Spago Nanomedical AB (Publ) Announces Interim Results from the Second Dose Group in Ongoing Clinical Phase I Study SPAGOPIX-01 Jan 14
Spago Nanomedical AB (Publ) Announces That Second Dose Group Fully Recruited in Spago Nanomedical's Phase 1 Study with Spagopix Dec 03
Third quarter 2021 earnings released Nov 12
Forecast to breakeven in 2022 Aug 26
Second quarter 2021 earnings released Aug 25
Full year 2020 earnings released: kr0.70 loss per share (vs kr1.01 loss in FY 2019) Apr 17 Shareholder Returns 7UX DE Biotechs DE Market 7D 9.0% -3.5% -2.0% 1Y -36.5% -14.7% 6.9%
See full shareholder returns
Return vs Market: 7UX underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 7UX's price volatile compared to industry and market? 7UX volatility 7UX Average Weekly Movement 12.1% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 7UX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7UX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
Show more Spago Nanomedical AB (publ) Fundamentals Summary How do Spago Nanomedical's earnings and revenue compare to its market cap? 7UX fundamental statistics Market cap €5.57m Earnings (TTM ) -€2.96m Revenue (TTM ) €607.03k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7UX income statement (TTM ) Revenue SEK 6.98m Cost of Revenue SEK 17.33m Gross Profit -SEK 10.34m Other Expenses SEK 23.75m Earnings -SEK 34.10m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.098 Gross Margin -148.10% Net Profit Margin -488.20% Debt/Equity Ratio 0%
How did 7UX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 12:47 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Spago Nanomedical AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Klas Palin Penser Access Johan Unnerus Redeye
Show 0 more analysts 